Researchers develop IrMn-cluster-based artificial metalloenzyme that integrates enzyme-mimetic catalysis, radiosensitization, and immune modulation to overcome cancer therapy limitations. The IMM accelerates ROS and O2 generation, relieving tumor hypoxia and activating systemic immune responses.
Researchers developed designer enzymes by transplanting a synthetic trinuclear zinc center into a human cytokine, resulting in a top-tier hydrolytic activity. The designer enzyme retained the original tautomerase activity, achieving dual functionality.
Researchers have discovered a new enzyme called CelOCE that can cleave cellulose using an unprecedented mechanism. This discovery has the potential to significantly increase the production of second-generation ethanol from agro-industrial waste, enabling the large-scale production of biofuels.
Jessica Lusty Beech wins award for understanding plastic-degrading Rieske iron oxidoreductase system, while Matteo Cagiada predicts absolute protein folding stability using generative models. The Protein Society recognizes their contributions to protein science.
UAB researchers have designed minimal nanozymes with the capacity to capture carbon dioxide, applicable for environmental remediation and biotechnology research. These new molecules are formed by peptides of only seven amino acids and can act as metalloenzymes, opening up possibilities in extreme temperatures and pH values.
The study reveals that enzyme ATE1 enhances activity upon binding iron-sulfur clusters and is sensitive to oxygen, moderating the cell's response to oxidative stress. This discovery could lead to new therapeutic targets for diseases tied to chronic cellular stress.
Researchers at RIKEN successfully treated cancer in mice using metal catalysts that assemble anticancer drugs inside the body. The technique avoids indiscriminate tissue damage and increases cancer-inhibiting activity by 1000 times.
Researchers at UC Berkeley engineered bacteria to produce an unnatural molecule through a combination of synthetic chemistry and biology. This breakthrough enables the creation of previously impossible chemicals, paving the way for sustainable materials and innovative products.
A team of researchers at RIKEN CPR has demonstrated a successful cancer therapy using artificial metalloenzymes to deliver targeted drug therapies. In mouse tests, they found a 40% survival rate for mice treated with selective cell therapy and a higher survival rate over 77 days when targeting tumors that had already formed.
Researchers develop an artificial metalloenzyme that protects a metal catalyst, allowing it to target cancer cells while sparing surrounding tissues. The system uses a sugar chain to guide the metalloenzyme to specific cells, delivering a potent anti-cancer compound.
Researchers at Berkeley Lab developed a hybrid enzyme capable of churning out 2,550 product molecules per hour, comparable to biological counterparts. The study represents a major advance for artificial metalloenzymes, which promise to open up a world of beneficial molecular products not currently possible with natural enzymes.
Scientists at the University of Basel have developed an artificial metalloenzyme, biot-Ru-SAV, that can catalyse olefin metathesis reactions in living cells. The breakthrough uses the periplasm as a reaction compartment to overcome limitations of organometallic-based enzymes.